CLINILABS HIRES SENIOR VICE PRESIDENT OF BUSINESS DEVELOPMENT
New York, NY (December 1, 2007) - Clinilabs, Inc. (“Clinilabs”) announced today that Dr. Francis Wouters has been hired as the Company's Senior Vice President of Business Development. Dr. Wouters, who assumed his position on November 1, 2007, will be responsible for leading the Company's initiatives related to the development and maintenance of relationships with pharmaceutical and biotechnology company clients.
"Clinilabs is pleased to welcome Dr. Wouters to its team of industry professionals," stated Dr. Gary Zammit, President and CEO of Clinilabs. "His extensive experience in contract research and clinical development will make him an invaluable contributor to our efforts to build productive relationships with the companies we serve."
Dr. Wouters has over 20 years of industry experience in North America and Europe. At his most recent position at PharmaNet Development Group, Inc., a global drug development services company, he served as Vice President of Business Development, Strategic Initiatives, and Office Head. He previously worked at MiniDoc, Inc., a company focused heavily on electronic data capture, as Vice President of Sales and Marketing.
Dr. Wouters received his doctorate in dental surgery from the University of Paris, France, and a post-doctoral degree in periodontology from the Karolinska Institute of Stockholm, Sweden. His background includes experience in neurology, pulmonology, cardiology, oncology, and periodontology.
Clinilabs is a global, specialty CRO that provides clinical development services to pharmaceutical and biotechnology companies involved in the development of central nervous system (CNS) and cardiovascular therapeutics. The Company offers a full portfolio of clinical contract research services, including scientific consulting, project management, study monitoring, data management, biostatistics, document preparation, regulatory, and patient recruitment.
Domestic and global multicenter projects are managed by the Company's clinical operations team, and supported by a core data center that provides centralized processing of source, case report form (CRF), electronic CRF, electroencephalographic (EEG), polysomnographic (PSG), electrocardiographic, blood pressure, and actigraphy data.
Single-center studies may be conducted at Clinilabs' site in Manhattan, which offers an ideal location for Phase I, biomarker, and proof-of-concept studies in any therapeutic area; PSG and EEG studies; and projects that require thorough QT or specialized cardiac assessment.
Established in 2001, Clinilabs has provided services to six of the world's top 20 pharmaceutical companies as well as to a large number of smaller pharmaceutical and biotechnology companies. The Company has been involved in the approval of six New Drug Applications (NDAs) and is dedicated to providing high quality, prompt, and cost-effective services to its clients in the interest of delivering new therapeutics to those in need.
The Company's website is www.clinilabs.com.
CONTACT
Mennato Forgione, Director of Business Development, Clinilabs, Inc.
mforgione@clinilabs.com, 212-994-4141
|
